These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30829809)

  • 1. Dupilumab for Systemic Allergy Syndrome With Dermatitis.
    Jacob SE; Sung CT; Machler BC
    Dermatitis; 2019; 30(2):164-167. PubMed ID: 30829809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis.
    Stout M; Silverberg JI
    J Am Acad Dermatol; 2019 Jul; 81(1):157-162. PubMed ID: 30885752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired responses of peripheral blood mononuclear cells to nickel in patients with nickel-allergic contact dermatitis and concomitant atopic dermatitis.
    Buchvald D; Lundeberg L
    Br J Dermatol; 2004 Mar; 150(3):484-92. PubMed ID: 15030331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case series of dupilumab-treated allergic contact dermatitis patients.
    Goldminz AM; Scheinman PL
    Dermatol Ther; 2018 Nov; 31(6):e12701. PubMed ID: 30246906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Unique Molecular Signatures of Contact Dermatitis and Implications for Treatment.
    Leonard A; Guttman-Yassky E
    Clin Rev Allergy Immunol; 2019 Feb; 56(1):1-8. PubMed ID: 29754191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective Use of Dupilumab in Managing Systemic Allergic Contact Dermatitis.
    Joshi SR; Khan DA
    Dermatitis; 2018; 29(5):282-284. PubMed ID: 30179979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Still elusive relationship between atopic dermatitis and allergic contact dermatitis.
    Wolf R; Orion E; Matz H; Lipozencić J
    Acta Dermatovenerol Croat; 2003 Dec; 11(4):247-50. PubMed ID: 14670226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review.
    Raffi J; Suresh R; Botto N; Murase JE
    J Am Acad Dermatol; 2020 Jan; 82(1):132-138. PubMed ID: 31562940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Helper 2 Inhibitors in Allergic Contact Dermatitis.
    Ludwig CM; Krase JM; Shi VY
    Dermatitis; 2021 Jan-Feb 01; 32(1):15-18. PubMed ID: 32496280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis.
    Chipalkatti N; Lee N; Zancanaro P; Dumont N; Kachuk C; Rosmarin D
    J Am Acad Dermatol; 2019 Apr; 80(4):1166-1167. PubMed ID: 30630024
    [No Abstract]   [Full Text] [Related]  

  • 11. Contact sensitivity in patients with recalcitrant atopic dermatitis.
    Tamagawa-Mineoka R; Masuda K; Ueda S; Nakamura N; Hotta E; Hattori J; Minamiyama R; Yamazaki A; Katoh N
    J Dermatol; 2015 Jul; 42(7):720-2. PubMed ID: 25808093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oleanolic acid acetate inhibits atopic dermatitis and allergic contact dermatitis in a murine model.
    Choi JK; Oh HM; Lee S; Park JW; Khang D; Lee SW; Lee WS; Rho MC; Kim SH
    Toxicol Appl Pharmacol; 2013 May; 269(1):72-80. PubMed ID: 23499868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response.
    Dhingra N; Shemer A; Correa da Rosa J; Rozenblit M; Fuentes-Duculan J; Gittler JK; Finney R; Czarnowicki T; Zheng X; Xu H; Estrada YD; Cardinale I; Suárez-Fariñas M; Krueger JG; Guttman-Yassky E
    J Allergy Clin Immunol; 2014 Aug; 134(2):362-72. PubMed ID: 24768652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contact allergy in atopic individuals in relation to allergen-specific immunotherapy.
    Siemund I; Hindsén M; Netterlid E; Güner N; Bruze M
    Eur J Dermatol; 2016 Jun; 26(3):271-80. PubMed ID: 27193374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silkworm dropping extract ameliorate trimellitic anhydride-induced allergic contact dermatitis by regulating Th1/Th2 immune response.
    Choi DW; Kwon DA; Jung SK; See HJ; Jung SY; Shon DH; Shin HS
    Biosci Biotechnol Biochem; 2018 Sep; 82(9):1531-1538. PubMed ID: 29806566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis.
    Neis MM; Peters B; Dreuw A; Wenzel J; Bieber T; Mauch C; Krieg T; Stanzel S; Heinrich PC; Merk HF; Bosio A; Baron JM; Hermanns HM
    J Allergy Clin Immunol; 2006 Oct; 118(4):930-7. PubMed ID: 17030248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
    Simpson EL; Bieber T; Guttman-Yassky E; Beck LA; Blauvelt A; Cork MJ; Silverberg JI; Deleuran M; Kataoka Y; Lacour JP; Kingo K; Worm M; Poulin Y; Wollenberg A; Soo Y; Graham NM; Pirozzi G; Akinlade B; Staudinger H; Mastey V; Eckert L; Gadkari A; Stahl N; Yancopoulos GD; Ardeleanu M;
    N Engl J Med; 2016 Dec; 375(24):2335-2348. PubMed ID: 27690741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sesquiterpene lactone mix patch testing supplemented with dandelion extract in patients with allergic contact dermatitis, atopic dermatitis and non-allergic chronic inflammatory skin diseases.
    Jovanović M; Poljacki M; Mimica-Dukić N; Boza P; Vujanović Lj; Duran V; Stojanović S
    Contact Dermatitis; 2004 Sep; 51(3):101-10. PubMed ID: 15479198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.